Monte Rosa’s MRT-6160 Enters Phase 2 Trial in Psoriatic Arthritis
Bitget2026/10/28 11:09- Novartis initiated a second Phase 2 study of Monte Rosa Therapeutics’ MRT-6160 (DDY391) in active moderate to severe psoriatic arthritis.
- The first patient visit triggers a $37.5 million milestone payment under the partners’ exclusive global development and commercialization license agreement.
- The randomized, placebo-controlled Phase 2a/b trial will evaluate efficacy, safety, tolerability and dose response.
- A Phase 2 trial in Sjögren’s disease began in August; additional Phase 2 study initiations could trigger further milestone payments.
- Phase 1 showed sustained, dose-dependent VAV1 degradation exceeding 90% in peripheral blood T cells, with no serious adverse effects observed.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley: Raised AbbVie’s target price to $346
Low base, high oil prices, and subsidies all drive growth: Tesla (TSLA.US) continues sales rebound in Northern Europe in October
In October of this year, registrations of new Tesla cars increased in several Nordic markets, continuing the recovery momentum of the American electric vehicle manufacturer's sales in the region.
Japan’s consumption is set for its first decline in over two years? The Bank of Japan preempts with a “precautionary statement”: Weak overall figures due to population shrinkage ≠ deteriorating demand, December rate hike may not be affected
The Bank of Japan stated that, due to the ongoing population decline, it is difficult for overall consumption in Japan to achieve strong growth. However, this also means that overall sluggish consumption does not necessarily indicate weakening household demand.
Swiss Franc remains stronger following SVME PMI data
Crypto prices
More
